Adjuvant cisplatin-based chemotherapy for stage I ovarian adenocarcinoma: a preliminary report

M S Piver; J Malfetano; T R Baker; S B Lele; D L Marchetti

doi:10.1016/0090-8258(89)90014-0

Adjuvant cisplatin-based chemotherapy for stage I ovarian adenocarcinoma: a preliminary report

Gynecol Oncol. 1989 Oct;35(1):69-72. doi: 10.1016/0090-8258(89)90014-0.

Authors

M S Piver¹, J Malfetano, T R Baker, S B Lele, D L Marchetti

Affiliation

¹ Department of Gynecologic Oncology, Roswell Park Memorial Institute, Buffalo, New York 14263.

PMID: 2792905
DOI: 10.1016/0090-8258(89)90014-0

Abstract

Thirty stage I patients with invasive ovarian adenocarcinoma were treated with 6 months of adjuvant induction cisplatin and monthly cisplatin, adriamycin, and cyclophosphamide. To date, 97% (29) are alive with no evidence of disease and normal CA-125 levels and 93% (28) are alive progression free with a median follow-up of 34 months (13-56).

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / mortality
Adenocarcinoma / pathology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cisplatin / administration & dosage
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Female
Humans
Laparotomy
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / mortality
Ovarian Neoplasms / pathology
Reoperation

Substances

Doxorubicin
Cyclophosphamide
Cisplatin

Supplementary concepts

CISCA protocol